Teva's Trouble Was Predicted. Path to Recovery Not as Clear - Bloomberg
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Teva to Sell Assets Such as Women's Health Unit to Cut Debt - Bloomberg
Teva's Credit Rating Cut to Junk by Fitch - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
US states accuse Teva and other drugmakers of colluding to inflate prices over 1,000%
The Pharma Job From Hell: Low Salary to Fix Sinking Giant Teva - Bloomberg
Teva CEO Kare Schultz Says Drugmaker Will Fight US Price-Fixing Charges - Bloomberg
Teva Pharmaceutical to Replace CEO Kare Schultz - WSJ
Teva Pharmaceutical Will Pay Over $4 Billion in Opioid Settlement - Bloomberg
Opioid Manufacturer Teva Pharmaceuticals Reaches $4B Global Settlement | Law.com
The Pharma Job From Hell: Low Salary to Fix Sinking Giant Teva - Bloomberg
Teva, Units Held Liable for Fueling N.Y. Opioid Crisis - Bloomberg
Teva CEO Steps Down After Patent Losses, Bribery Settlement; Stock Dives | Stock News & Stock Market Analysis - IBD
Teva's Budding Blockbuster Drugs Lend Respite From Legal Concerns - Bloomberg
Teva Pharmaceuticals to pay New York $523 million to settle claims from its role in opioids crisis - ABC News
The Pharma Job From Hell: Low Salary to Fix Sinking Giant Teva - Bloomberg
Teva's Working With Evercore to Review Debt Options - Bloomberg
Teva's Adderall Shortage Seen Continuing Into March (TEVA) - Bloomberg
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters
Teva Poised to Face U.S. Charges in Drug Price-Fixing Probe - Bloomberg
Teva CEO Resigns; Dividend Cut Should Be Next - Bloomberg
Teva Sees Adderall Supply Delays Continuing for 2-3 Months (1)
Teva Pharma's Short Sellers Double Down as Legal Woes Drag On - Bloomberg
